

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Fiscal 2012 Interim Consolidated Financial Statements**

Interim results for Fiscal 2012  
(January 1, 2012 - June 30, 2012)

<b>Index</b>	<b>Page</b>
I. Consolidated Financial results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/losses	2
5. R&D expenses	3
6. Capital expenditure (tangible fixed assets)	3
7. Depreciation expenses	3
8. Exchange rates	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net sales by division	
1. Kyowa Hakko Kirin	5
2. ProStrakan	6
3. Kyowa Hakko Bio	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the first half of Fiscal 2012, the six-month period from January 1, 2012 to June 30, 2012. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## I. Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	FY2011 results			FY 2012 results				FY 2012 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January to June 2011		
						Amount (B-A)	%	
<b>Net sales</b>	114,862	186,367	343,722	87,111	166,290	(20,077)	-11%	333,000
<b>Gross Profit</b>	56,644	100,234	197,555	55,016	104,321	4,087	4%	--
Selling, general and administrative expenses	34,734	70,297	150,940	36,976	78,736	8,438	12%	--
<b>Operating income (prior to amortization of goodwill)</b>	24,235	34,576	55,881	20,353	30,212	(4,364)	-13%	61,255
<b>Operating income</b>	21,909	29,936	46,614	18,039	25,585	(4,351)	-15%	52,000
Non-operating income	1,280	1,316	2,233	1,660	1,419	102	--	--
Non-operating expenses	937	1,040	2,093	3,125	3,909	2,869	--	--
<b>Ordinary income</b>	22,252	30,212	46,754	16,575	23,094	(7,118)	-24%	46,500
Extraordinary income	8,265	8,421	7,332	-	-	(8,421)	--	--
Extraordinary loss	3,214	5,363	7,903	324	324	(5,038)	--	--
<b>Net income before income taxes</b>	27,304	33,270	46,183	16,250	22,769	(10,500)	-32%	45,500
Corporate, local and enterprise taxes	12,496	15,507	20,489	7,719	11,212	(4,294)	--	--
Income from minority interests	22	44	86	16	32	(12)	--	--
<b>Net income</b>	14,785	17,718	25,608	8,514	11,523	(6,194)	-35%	23,000
Comprehensive income	15,426	16,745	18,693	15,003	13,356	-3,389	-20%	--
EPS before goodwill amortization (¥/share)	30.03	39.24	61.50	19.66	29.40			58.81

1. On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its subsidiaries were newly included in the scope of consolidation. In terms of accounting treatment, June 30, 2011 is considered as the date that the acquisition was completed and therefore results from ProStrakan are included in the consolidated financial results of the current fiscal year.
2. Figures for FY2012 forecasts are those as announced July 19, 2012.

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	FY 2011 results			FY 2012 results				FY 2012 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January to June 2011		
						Amount (B-A)	%	
<b>Net sales</b>	114,862	186,367	343,722	87,111	166,290	(20,077)	-11%	333,000
Pharmaceuticals	63,393	112,534	229,339	64,870	122,833	10,298	9%	248,000
Bio-Chemicals	19,686	40,360	77,563	20,589	40,082	(278)	-1%	79,000
Chemicals	33,550	33,550	33,550	--	--	(33,550)	--	--
Other	2,651	5,306	10,659	2,557	5,173	(133)	-3%	10,000
Total	119,281	191,752	351,113	88,016	168,088	(23,663)	-12%	337,000
Eliminations	(4,419)	(5,384)	(7,390)	(905)	(1,798)	3,585	--	(4,000)
<b>Operating income</b>	21,909	29,936	46,614	18,039	25,585	(4,351)	-15%	52,000
<i>*Before goodwill amortization</i>	24,235	34,576	55,881	20,353	30,212	(4,364)	-13%	61,255
Pharmaceuticals	18,419	25,145	41,314	16,638	23,364	(1,781)	-7%	48,700
Bio-Chemicals	2,076	29,459	49,942	18,795	27,678	(1,781)	-6%	57,329
Chemicals	1,272	2,519	2,896	1,303	2,040	(479)	-19%	3,000
Other	1,428	2,832	3,521	1,459	2,353	(479)	-17%	3,626
Chemicals	2,135	2,135	2,135	--	--	(2,135)	--	--
Other	2,147	2,147	2,147	--	--	(2,147)	--	--
Other	82	148	360	94	155	7	5%	300
Total	21,909	29,948	46,706	18,036	25,560	(4,388)	-15%	52,000
Eliminations	24,235	34,588	55,973	20,349	30,187	(4,400)	-13%	61,255
Eliminations	0	(12)	(92)	3	24	36	--	--

#### Notes:

1. Figures representing amounts before goodwill amortization have been italicized.
2. The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals was consolidated on the Statements of Income only until March 31, 2011.

## (2) Regional sales

Millions of yen, rounded down

	FY2011 results						FY 2012 results			
	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales
<b>Japan sales</b>	91,329	79.5%	148,987	79.9%	272,568	79.3%	68,921	79.1%	128,898	77.5%
<b>Overseas sales</b>	23,532	20.5%	37,379	20.1%	71,154	20.7%	18,189	20.9%	37,391	22.5%
America	6,837	6.0%	10,456	5.6%	20,071	5.8%	4,638	5.3%	10,097	6.1%
Europe	6,060	5.3%	10,919	5.9%	25,169	7.3%	8,427	9.7%	16,927	10.2%
Asia	10,499	9.1%	15,772	8.5%	25,426	7.4%	4,997	5.7%	10,088	6.1%
Other regions	135	0.1%	231	0.1%	486	0.1%	127	0.1%	278	0.2%
<b>Total consolidated net sales</b>	<b>114,862</b>	<b>100.0%</b>	<b>186,367</b>	<b>100.0%</b>	<b>343,722</b>	<b>100.0%</b>	<b>87,111</b>	<b>100.0%</b>	<b>166,290</b>	<b>100.0%</b>

## 3. Trends in non-operating income/expenses

Millions of yen, rounded down

	FY2011 results			FY 2012 results	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30
<b>Non-operating income</b>	1,280	1,316	2,233	1,660	1,419
Interest income	65	193	497	142	285
Dividend income	57	303	536	318	442
Foreign exchange gains	579	112	--	926	--
Gain on revaluation of derivatives	--	--	--	--	16
Equity in earnings of affiliates	166	141	199	--	--
Other	411	565	1,000	273	675
<b>Non-operating expenses</b>	937	1,040	2,093	3,125	3,909
Interest expenses	43	77	135	32	81
Foreign exchange loss	--	--	154	--	45
Loss on revaluation of derivatives	431	32	142	292	--
Equity in losses of affiliates	--	--	--	2,465	2,549
Loss on disposal of non-current assets	165	313	670	115	414
Other	296	617	990	218	818

## 4. Trends in extraordinary income / loss

Millions of yen, rounded down

	FY 2011 results			FY 2012 results	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30
<b>Extraordinary income</b>	8,265	8,421	7,332	--	--
Gain on sales of subsidiaries and affiliates' stocks	8,265	8,320	7,217	--	--
Reversal of allowance for doubtful accounts	--	100	115	--	--
<b>Extraordinary loss</b>	3,214	5,363	7,903	324	324
Loss on sale of investment securities	--	--	692	324	324
Loss on valuation of investment securities	1,546	3,043	2,374	--	--
Advisory expenses	973	1,030	1,098	--	--
Asset impairment loss	--	200	769	--	--
Loss from natural disaster	118	302	650	--	--
Loss from sale of fixed assets	--	--	635	--	--
Extraordinary depreciation of fixed assets	--	--	477	--	--
Loss on adjustment for changes of accounting standard for asset retirement	447	447	447	--	--
Loss on business liquidation	--	--	419	--	--
Loss on liquidation of affiliates	--	209	209	--	--
Provision for point card certificates for prior periods	128	128	128	--	--

## 5. Trends in R&D expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>R&amp;D expenses (Consolidated)</b>	10.8	22.2	47.9	11.0	22.1	44.3
R&D to net sales ratio (%)	9.4%	11.9%	14.0%	12.7%	13.3%	13.3%
Pharmaceuticals	9.8	20.4	44.5	10.3	20.5	41.0
(R&D to net sales ratio) (%)	15.6%	18.2%	19.4%	15.9%	16.8%	16.5%
Bio-Chemicals	0.7	1.5	3.2	0.7	1.5	3.3
Chemicals	0.2	0.2	0.2	--	--	--
Other	--	--	--	--	--	--

## 6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>Capital expenditure (Consolidated)</b>	3.1	5.9	14.3	4.1	7.9	21.4
Pharmaceuticals	1.4	2.8	6.5	2.1	4.0	10.9
Bio-Chemicals	1.3	2.7	7.4	1.9	3.9	10.4
Chemicals	0.3	0.3	0.3	--	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 7. Trends in Depreciation Expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>Depreciation expenses (Consolidated)</b>	5.5	10.4	22.8	4.6	9.6	21.3
Pharmaceuticals	3.3	6.8	15.3	3.1	6.6	14.5
Bio-Chemicals	1.2	2.6	6.4	1.5	2.9	6.7
Chemicals	0.9	0.9	0.9	--	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 8. Exchange rates

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	82	82	80	79	80	81
Euro (¥/Euro)	113	115	111	104	103	102
GBP (¥/GBP)	132	133	128	125	126	124

## II. Consolidated Subsidiaries and Affiliates

(As of June 30, 2012)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
			Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a.r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)	
	Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
		Kyowa Hakko Kirin Korea Co., Ltd.	90.0%	Sales of pharmaceuticals (Korea)	
		Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)	
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Sales of pharmaceuticals (Singapore)		
Affiliate accounted by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar products	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
Kyowa Hakko (H.K.) Co., Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Hong Kong)		
Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Singapore)		
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: Changes to the scope of consolidation (January 1, 2012 to June 30, 2012)

Newly consolidated: 1 company: ProStrakan AB (\*1)

Removed: 1 company: Kyowa Hakko Kirin Italia S.r.l. (\*2)

\*1 On June 1, 2012, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan AB and was newly included as a subsidiary in the scope of consolidation.

\*2 As of June 1, 2012, Kyowa Hakko Kirin Italia S.r.l. was merged with ProStrakan S.r.l. and eliminated.

\*3 Kirin Kungpeng (China) Bio-Pharmaceutical Co., Ltd. changed its corporate name to Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.

\*4. Jeil-Kirin Pharm. Inc. changed its corporate name to Kyowa Hakko Kirin Korea Co., Ltd.

### III. Net sales by division (Items and main products)

#### 1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	Fiscal 2011 results			Fiscal 2012 results			FY 2012 forecasts
	January 1 to March 31 results	January 1 to June 30 results (A)	January 1 to December 31 results	January 1 to March 31 results	January 1 to June 30 results (B)	Change on January 1 to June 30, 2011 (B/A)	January 1 to December 31
<b>Pharmaceuticals division total</b>	59.8	104.6	206.0	57.8	107.8	3%	213.9
<b>Indication / Product</b>							
<i>ESA formulation</i>							
<b>Nesp</b>	11.9	25.4	56.4	13.8	26.8	5%	53.7
<i>ESA formulation</i>							
<b>Espo</b>	1.3	2.7	5.3	0.9	1.9	-29%	4.0
<b>Nesp/Espo</b>	(13.3)	(28.2)	(61.8)	(14.8)	(28.8)	(+2%)	(57.7)
<i>Secondary hyperparathyroidism</i>							
<b>Regpara</b>	2.5	5.3	11.5	2.8	6.2	17%	13.0
<i>Antiallergenic</i>							
<b>Allelock</b>	13.7	18.1	29.1	9.9	16.1	-11%	29.1
<i>Antiallergenic</i>							
<b>Celtect</b>	0.7	1.3	2.5	0.5	1.0	-26%	1.8
<i>Antiallergic eyedrops</i>							
<b>Patanol</b>	7.3	8.6	11.4	5.4	6.9	-20%	10.1
<i>G-CSF</i>							
<b>Gran</b>	3.3	6.7	14.8	2.9	6.4	-5%	13.4
<i>Cancer pain</i>							
<b>Fentos</b>	0.4	1.2	3.1	0.8	2.0	70%	4.5
<i>Anticancer</i>							
<b>5-FU</b>	0.7	1.5	3.1	0.6	1.4	-10%	2.7
<i>Anticancer</i>							
<b>Navelbine</b>	0.4	0.8	1.7	0.3	0.6	-25%	1.2
<i>Cardiovascular</i>							
<b>Coniel</b>	4.6	9.6	19.7	4.2	8.5	-11%	17.2
<i>Cardiovascular (Hypertension)</i>							
<b>Coversyl</b>	0.9	1.9	3.9	0.8	1.7	-10%	3.4
<i>Cardiovascular</i>							
<b>Inovan / Pre Dopa</b>	0.7	1.3	2.8	0.6	1.1	-15%	2.4
<i>Antiepileptic</i>							
<b>Depakene</b>	2.6	5.3	11.2	2.4	5.2	-3%	10.8
<i>Parkinson's disease</i>							
<b>Permax</b>	0.5	1.1	2.1	0.3	0.8	-21%	1.7
<i>Gastrointestinal</i>							
<b>Nauzelin</b>	1.2	2.3	4.8	1.1	2.2	-3%	4.7
<i>Inflammatory bowel disease</i>							
<b>Asacol</b>	0.5	1.1	2.8	0.8	1.8	52%	3.8
<b>Exports and Technology Out-Licensing</b>	7.6	11.4	22.3	11.3	17.9	57%	34.7

## 2. ProStrakan

Millions of GBP, rounded down

Pharmaceuticals division	FY 2011 results			FY 2012 results			FY 2012 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30, 2012 (B)	Change on January to June 2011 (B/A)	January 1 to December 31
<b>Net sales</b>	23	48	105	29	61	27%	139
Chemotherapy-induced nausea and vomiting drug <b>Sancuso</b>	2	4	9	2	5	47%	16
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. <b>Abstral</b>	5	12	27	7	16	29%	36
Replacement therapy with testosterone for male hypogonadism <b>Tostran</b>	0	2	5	1	2	32%	4
Prevention and treatment of post-operative nausea and vomiting (PONV). <b>Xomolix</b>	2	4	8	2	4	-7%	9
Relief of pain associated with chronic anal fissures <b>Rectogesic</b>	2	4	9	2	4	0%	9
Osteoporosis drug <b>Adcal-D3</b>	5	11	24	5	12	7%	25
<b>Others</b>	4	8	20	6	14	74%	37
<b>Gross profit</b>	15	29	65	19	40	41%	101
Selling, general and administrative expenses	18	40	75	18	39	-3%	84
<b>Operating income (prior to consolidated adjustment)</b>	(3)	(11)	(9)	0	1	--	17
Consolidated adjustment				(9)	(18)		(34)
<b>Operating income (after consolidated adjustment)</b>				(8)	(16)		(17)

- Notes: 1. ProStrakan has been included in the consolidated results as of July 2011  
2. FY 2011 results based on ProStrakan local accounting standards (IFRS) while FY 2012 forecasts are shown on a consolidated basis. Consolidated adjustment amounts are for noncurrent intangible assets (sales rights, etc.) and the amortization of the goodwill resulting from the occurrence of goodwill following the acquisition of ProStrakan Group plc. Operating income (after consolidated adjustment) are Kyowa Hakkō Kirin figures after consolidation.  
3. Sales ratio by region as follows:

*Sales ratio by region (January 1 to June 30, 2012)	UK	Europe (excluding UK)	USA	Other	Total
	33.3%	44.4%	20.8%	1.5%	100.0%

## 3. Kyowa Hakkō Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	FY 2011 results			FY 2012 results			FY 2012 forecasts
	January 1 to March 31	January 1 to June 30 (A)	January 1 to December 31	January 1 to March 31	January 1 to June 30 (B)	Change on January to June 2011 (B/A)	January 1 to December 31
<b>Bio-Chemical division total</b>	12.3	25.9	49.6	12.9	25.9	100%	52.1
<b>Pharmaceuticals / Industrial raw materials</b>							
<b>Amino acids</b>	4.5	10.1	19.1	5.0	10.2	100%	20.6
<b>Nucleic acids and vitamins</b>	1.2	2.7	5.2	1.3	2.5	95%	5.2
<b>Other</b>	1.7	3.8	7.2	1.7	3.7	97%	6.6
<b>Health care products</b>	2.1	4.7	9.3	2.2	4.7	100%	10.1

Filed • Approved



antibody



protein



small molecule







As of Jul 17th 2012

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	<b>Pegfilgrastim Injection</b>	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Approved in Korea and Vietnam	Kirin- Amgen	
	<b>Cinacalcet Hydrochloride Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in Asia	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
	<b>KW-6002 Istradefylline Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Filed in USA  Filed in Japan	In-House	
	<b>AMG531 Romiplostim Injection</b>	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in Taiwan	Kirin- Amgen	
	<b>Granisetron Patch</b>	5HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in Asia	Solasia Pharma (ProStrakan)	Asia: Taiwan and Singapore Launched by ProStrakan as Sancuso






**Phase II, Phase III**

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	<b>KW-2246 Fentanyl citrate Sublingual Tablet</b>	$\mu$ -Opioid Receptor Agonist	Cancer Pain	Phase III in Japan	Licensed from Orexo	Launched by ProStrakan as Abstral.
	<b>KRN125 Pegfilgrastim Injection</b>	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Phase III in Japan	Kirin- Amgen	
	<b>ARQ 197 Tivantinib Oral</b>	c-Met Inhibitor	Lung Cancer  Gastric Cancer	Phase III in Japan, Korea and Taiwan  Phase II in Japan and Korea	Licensed from ArQule	
	<b>KRN321 Darbepoetin Alfa Injection</b>	Long-Acting Erythropoiesis Stimulating Agent	☆ Pediatric Renal Anemia  Renal Anemia (on Dialysis)  ☆ Myelodysplastic Syndrome related Anemia	Phase III in Japan  Phase II in China Phase III in India  Phase II in Japan and Korea	Kirin- Amgen	Launched in Japan for Anemia of CKD Patients
	<b>KRN1493 Cinacalcet Hydrochloride Oral</b>	Calcium Receptor Agonist	☆ Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase III in Japan	Licensed from NPS	Launched in Japan for Secondary Hyperparathyroidism
	<b>KW-6485 Topiramate Oral</b>	Antiepileptic Drug	☆ Pediatric Epilepsy	Phase III in Japan	Licensed from Janssen Pharmaceu tical K.K.	Launched in Japan for Use as an Antiepileptic Drug
	<b>KW-3357 Antithrombin Injection</b>	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in Japan Phase I in Europe	In-House	
	<b>KW-0761 Mogamulizumab Injection</b>	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)  Peripheral T/NK-cell Lymphoma  Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma  Peripheral T-cell Lymphoma	Phase II in Japan  Phase II in Japan  Phase I / II in USA  Phase II in EU	In-House	POTELLIGENT®



	<b>KW-2478</b> Injection	HSP90 inhibitor	Multiple Myeloma	Phase I / II in UK/US/PH	In-House	
	<b>ASKP1240</b> Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in Japan Phase II in USA	In-House	Jointly Developed with Astellas KM mouse
	<b>RTA 402</b> Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase II in Japan	Licensed from Reata	
	<b>KHK4563</b> Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase II in Japan and Korea	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIGENT®
	<b>KHK6188</b> Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase II in Japan	In-House	
	<b>Z-206</b> Mesalazine Oral	pH Dependent Controlled Release Tablet	☆ Crohn's Disease	Phase II in Japan	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma Launched in Japan for Ulcerative Colitis.

### Phase I

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	<b>KW-2450</b> Oral	IGF-1 Receptor Signal Inhibitor	Cancer	Phase I / II in USA	In-House	
	<b>KRN330</b> Injection	Anti-A33 Fully Human Antibody	Cancer	Phase I / IIa in USA	In-House	KM mouse
	<b>BIW-8962</b> Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / IIa in USA	In-House	POTELLIGENT®
	<b>KRN951</b> Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in Japan	In-House	
	<b>KHK2866</b> Injection	Anti-HB-EGF Humanized Antibody	Cancer	Phase I in USA	In-House	POTELLIGENT®
	<b>LY2523355</b> Litronesib Injection	M phase Kinesin Eg5 Inhibitor	Cancer	Phase I in Japan	In-House	
	<b>CEP-37250/KH K2804</b> Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in USA	Cephalon	Jointly Developed with Cephalon POTELLIGENT®
	<b>KHK2898</b> Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in Singapore	In-House	POTELLIGENT® KM mouse
	<b>KW-0761</b> Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	☆ Asthma	Phase I in Japan	In-House	POTELLIGENT®
	<b>KHK4827</b> Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase I in Japan	Kirin- Amgen	
	<b>KRN23</b> Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in USA and Canada	In-House	KM mouse


Updated since Apr 18th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication



Updated since Apr 18th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

### Filed • Approved

As of Jul 17th 2012

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	<b>Pegfilgrastim</b> Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Approved in Korea and Vietnam	Kirin- Amgen	

### Phase II, Phase III

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	<b>KW-0761</b> Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T-cell Lymphoma	Phase II in EU	In-House	POTELLIGENT®
	<b>KHK6188</b> Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase II in Japan	In-House	